Alzheimer’s Treatment Market Outlook (2024 – 2032)

The global market for Alzheimer’s treatments is projected to expand significantly, growing from approximately USD 4.82 billion in 2023 to over USD 8.18 billion by 2032. This growth reflects a robust compound annual growth rate (CAGR) of 8.7% during the forecast period from 2024 to 2032.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5130

Report Highlights

Cholinesterase inhibitors led the Alzheimer’s treatment market in 2023, accounting for 50% of sales.
Combination drugs are expected to grow the fastest, with an estimated 6.2% annual growth rate through 2032.
Hospital pharmacies were the primary source of Alzheimer’s treatments in 2023.

Alzheimer’s disease is a devastating condition that affects memory, thinking, and daily living. It happens because brain cells die due to changes in the brain. People with Alzheimer’s may struggle with remembering, communicating, and even taking care of themselves.

The exact cause of Alzheimer’s isn’t completely understood, but experts believe it’s due to a mix of genetics, environment, and lifestyle. Aging is the biggest risk factor, but younger people can also get it. Women are more likely to develop Alzheimer’s because they tend to live longer than men.

In 2021, around 6.2 million Americans aged 65 and older had Alzheimer’s. This number could double to nearly 13.8 million by 2060 if new treatments to stop or slow the disease aren’t developed. Alzheimer’s has become one of the leading causes of death among neurodegenerative diseases and often leaves people physically disabled, making timely treatment essential.

While there’s no cure for Alzheimer’s yet, treatments can help manage symptoms and slow its progression. These include medications that boost memory and therapies that support communication and daily tasks. Early diagnosis is critical to helping people with Alzheimer’s maintain independence and quality of life for as long as possible.

Caring for someone with Alzheimer’s can be challenging. It’s essential to create a safe, supportive environment and provide emotional and practical help for caregivers. Effective management of Alzheimer’s can improve life for both patients and their families, ensuring they have the resources and support they need.

Recent Developments

In 2021, Amneal expanded its capabilities by acquiring Kashiv Specialty Pharmaceuticals, gaining access to a portfolio of complex generic and branded medicines.

In March 2022, Biogen and Eisai strengthened their collaboration to advance treatments for Alzheimer’s disease.

In October 2022, Cyclo Therapeutics began its Phase 2b study of Trappsol Cyclo, a potential treatment for Alzheimer’s designed to target amyloid beta and tau proteins. The study received approval from the Institutional Review Board (IRB).

In September 2022, Eisai and Biogen shared promising results from the Phase 3 Clarity AD trial of lecanemab. This investigational antibody showed potential for treating mild cognitive impairment and early-stage Alzheimer’s linked to amyloid beta.

Key Companies in the Alzheimer’s Treatment Market

• Biogen Inc.
• Eli Lilly and Company
• Eisai Co., Ltd.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Johnson & Johnson Services Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• AbbVie Inc.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/alzheimers-therapeutics-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5130

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare